Free Trial
Earnings Season Is Here. MarketBeat All Access for Just $149
  • 0Days
  • 0Hours
  • 0Minutes
  • 0Seconds
Get the Deal
Claim MarketBeat All Access Sale Promotion
NASDAQ:TVTX

Travere Therapeutics Q3 2026 Earnings Date & Estimates

Travere Therapeutics logo
$50.85 -0.03 (-0.06%)
Closing price 04:00 PM Eastern
Extended Trading
$50.29 -0.56 (-1.11%)
As of 05:40 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Travere Therapeutics is scheduled to report Q3 2026 earnings on Monday, November 2, 2026, after market closes. The conference call is scheduled for 4:30 PM ET.

Research:ProfileEarnings HistoryForecast

Upcoming Earnings Announcement

Quarter
Q3 2026
Announcement Date
Time
After Market Closes
Conference Call
4:30 PM ET
Google Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab)

What Analysts Expect from Travere Therapeutics in Q3 2026

Travere Therapeutics is expected to post earnings of -$0.25 per share on revenue of $198.32 million. In the same quarter a year earlier Travere Therapeutics reported $0.28 per share on revenue of $164.86 million. Travere Therapeutics last reported on August 4, 2026, posting -$0.10 per share and beating the -$0.1347 consensus estimate. Travere Therapeutics has beaten the consensus EPS estimate in 6 of its last 8 quarters.

Consensus Estimates

Consensus EPS
-$0.25
Expected Revenue
$198.32 million
Prior-Year EPS
$0.28
Prior-Year Revenue
$164.86 million
Expected EPS Growth
-189.3%
Expected Revenue Growth
+20.3%

Recent Track Record

Last Reported
Q2 2026
Last Quarter EPS
-$0.10 (Beat by +$0.0347)
Last Quarter Revenue
$169.58 million
EPS Beat Rate
6 of last 8 quarters

Prepare for the Q3 2026 Call

Travere Therapeutics Q3 2026 Earnings FAQ

Travere Therapeutics (NASDAQ:TVTX) has confirmed it will report Q3 2026 earnings on Monday, November 2, 2026, after market closes.

Travere Therapeutics' Q3 2026 earnings conference call is scheduled for Monday, November 2, 2026 at 4:30 PM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date.

Analysts expect Travere Therapeutics to post earnings of -$0.25 per share for Q3 2026.

The consensus revenue estimate for Travere Therapeutics is $198.32 million for Q3 2026.

Travere Therapeutics Earnings Headlines

Travere Therapeutics to Report Third Quarter 2026 Financial Results
October 26 at 5:00 PM  |  businesswire.comhttps://www.businesswire.com/news/home/20261026641403/en/Travere-Therapeutics-to-Report-Third-Quarter-2026-Financial-Results/
Travere Therapeutics, Inc. Presents New Biomarker Data From Phase 3 PROTECT Study Suggesting FILSPARI® May Modify Underlying Disease Pathophysiology In IgA Nephropathy
October 23, 2026  |  marketscreener.comM
The chip inside every Tesla
Every Tesla built since 2012 pays this small, overlooked supplier a fee for its technology. So does every Starlink dish and AI satellite Elon launches. When Nvidia tried to buy the company, Elon reportedly fought the deal. Now his filing for 1,000,000 satellites could expand its revenue stream sharply. Dylan believes the stock could see significant movement starting December 8th.tc pixel
October 28 at 1:00 AM  |  Behind the Markets (Ad)
Travere Presents New Biomarker Data at ASN Kidney Week Suggesting FILSPARI® (sparsentan) May Modify Underlying Disease Pathophysiology in IgA Nephropathy
October 23, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20261023530930/en/travere-presents-new-biomarker-data-at-asn-kidney-week-suggesting-filspari%c2%ae-sparsentan-may-modify-underlying-disease-pathophysiology-in-iga-nephropathy/
Travere Therapeutics (TVTX) Set to Release Quarterly Earnings on Thursday
October 22, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31145364
Travere Therapeutics (NASDAQ:TVTX) Stock: Insider Eric Dube Sells 243,735 Shares
October 21, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31142359
See More Travere Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Travere Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Travere Therapeutics and other key companies, straight to your email.

About Travere Therapeutics

Travere Therapeutics (NASDAQ:TVTX) is a biopharmaceutical company focused on developing and commercializing therapies for rare diseases, with an emphasis on serious kidney conditions. The company’s work centers on addressing diseases with limited treatment options and improving outcomes for patients with progressive renal disorders.

Travere’s lead commercial product is FILSPARI (sparsentan), an oral treatment for adults with primary immunoglobulin A nephropathy (IgA nephropathy) who are at risk of disease progression. The company has also developed therapies for other rare kidney disorders, including cystinuria, a genetic condition that can cause recurrent kidney stones.

The company was founded in 2008 as Retrophin and adopted the Travere Therapeutics name in 2020. Its operations are based in San Diego, California, and its products and development programs serve patients and healthcare providers primarily in the United States, with efforts to expand access in additional markets. Eric M. Dube has served as the company’s president and chief executive officer.

View Travere Therapeutics Profile
Earnings Tools